Easywell Biomedicals Inc.
Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. It operates through Drug Development and Other segments. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and … Read more
Easywell Biomedicals Inc. (1799) - Net Assets
Latest net assets as of June 2024: NT$745.19 Million TWD
Based on the latest financial reports, Easywell Biomedicals Inc. (1799) has net assets worth NT$745.19 Million TWD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.40 Billion) and total liabilities (NT$653.80 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$745.19 Million |
| % of Total Assets | 53.27% |
| Annual Growth Rate | -2.73% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 16.32 |
Easywell Biomedicals Inc. - Net Assets Trend (2019–2023)
This chart illustrates how Easywell Biomedicals Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Easywell Biomedicals Inc. (2019–2023)
The table below shows the annual net assets of Easywell Biomedicals Inc. from 2019 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | NT$623.80 Million | -19.05% |
| 2022-12-31 | NT$770.56 Million | -15.52% |
| 2021-12-31 | NT$912.09 Million | +19.46% |
| 2020-12-31 | NT$763.52 Million | +9.56% |
| 2019-12-31 | NT$696.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Easywell Biomedicals Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2319000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$1.16 Billion | 189.07% |
| Other Components | NT$24.31 Million | 3.97% |
| Total Equity | NT$612.81 Million | 100.00% |
Easywell Biomedicals Inc. Competitors by Market Cap
The table below lists competitors of Easywell Biomedicals Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Minsud Resources Corp
PINK:MDSQF
|
$62.17 Million |
|
Neo Battery Materials Ord Shs
V:NBM
|
$62.17 Million |
|
Kellton Tech Solutions Limited
NSE:KELLTONTEC
|
$62.18 Million |
|
NewFlex Technology Co. Ltd
KQ:085670
|
$62.18 Million |
|
Hafnia Limited
NYSE:HAFN
|
$62.14 Million |
|
Daldrup & Söhne Aktiengesellschaft
F:4DS
|
$62.10 Million |
|
Maisons du Monde S.A
PINK:MDOUF
|
$62.08 Million |
|
Liquidmetal Technologies Inc
OTCQB:LQMT
|
$62.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Easywell Biomedicals Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 738,464,000 to 612,813,000, a change of -125,651,000 (-17.0%).
- Net loss of 144,818,000 reduced equity.
- Other factors increased equity by 19,167,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-144.82 Million | -23.63% |
| Other Changes | NT$19.17 Million | +3.13% |
| Total Change | NT$- | -17.02% |
Book Value vs Market Value Analysis
This analysis compares Easywell Biomedicals Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.19x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 4.27x to 6.19x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$7.69 | NT$32.80 | x |
| 2020-12-31 | NT$7.47 | NT$32.80 | x |
| 2021-12-31 | NT$8.39 | NT$32.80 | x |
| 2022-12-31 | NT$6.39 | NT$32.80 | x |
| 2023-12-31 | NT$5.30 | NT$32.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Easywell Biomedicals Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -23.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -53.31%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.98x
- Recent ROE (-23.63%) is above the historical average (-25.48%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -40.12% | -75.51% | 0.31x | 1.73x | NT$-339.54 Million |
| 2020 | -24.63% | -64.79% | 0.24x | 1.57x | NT$-243.81 Million |
| 2021 | -17.21% | -76.23% | 0.16x | 1.45x | NT$-237.76 Million |
| 2022 | -21.80% | -90.00% | 0.15x | 1.59x | NT$-234.85 Million |
| 2023 | -23.63% | -53.31% | 0.22x | 1.98x | NT$-206.10 Million |
Industry Comparison
This section compares Easywell Biomedicals Inc.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,954,182,000
- Average return on equity (ROE) among peers: 8.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Easywell Biomedicals Inc. (1799) | NT$745.19 Million | -40.12% | 0.88x | $62.14 Million |
| Grape King Bio Ltd (1707) | $11.79 Billion | 12.28% | 0.30x | $413.97 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.14 Billion | 10.26% | 0.37x | $160.24 Million |
| Maywufa Co Ltd (1731) | $2.11 Billion | 8.22% | 0.51x | $41.33 Million |
| Allied Biotech Corporation (1780) | $1.17 Billion | 8.33% | 0.78x | $47.92 Million |
| ScinoPharm Taiwan Ltd (1789) | $9.38 Billion | 5.16% | 0.21x | $180.77 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $24.30 Million |
| LIWANLI Innovation Co Ltd (3054) | $799.59 Million | 4.48% | 0.55x | $49.55 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $292.12 Million |
| TTY Biopharm Co Ltd (4105) | $6.11 Billion | 22.00% | 0.56x | $486.74 Million |